1. Home
  2. BIIB vs TXT Comparison

BIIB vs TXT Comparison

Compare BIIB & TXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • TXT
  • Stock Information
  • Founded
  • BIIB 1978
  • TXT 1923
  • Country
  • BIIB United States
  • TXT United States
  • Employees
  • BIIB N/A
  • TXT N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • TXT Aerospace
  • Sector
  • BIIB Health Care
  • TXT Industrials
  • Exchange
  • BIIB Nasdaq
  • TXT Nasdaq
  • Market Cap
  • BIIB 18.7B
  • TXT 14.3B
  • IPO Year
  • BIIB 1991
  • TXT N/A
  • Fundamental
  • Price
  • BIIB $168.52
  • TXT $80.88
  • Analyst Decision
  • BIIB Buy
  • TXT Buy
  • Analyst Count
  • BIIB 24
  • TXT 11
  • Target Price
  • BIIB $174.62
  • TXT $92.45
  • AVG Volume (30 Days)
  • BIIB 1.7M
  • TXT 1.5M
  • Earning Date
  • BIIB 10-30-2025
  • TXT 10-23-2025
  • Dividend Yield
  • BIIB N/A
  • TXT 0.10%
  • EPS Growth
  • BIIB N/A
  • TXT N/A
  • EPS
  • BIIB 10.97
  • TXT 4.55
  • Revenue
  • BIIB $10,065,900,000.00
  • TXT $14,237,000,000.00
  • Revenue This Year
  • BIIB $2.97
  • TXT $8.63
  • Revenue Next Year
  • BIIB N/A
  • TXT $4.95
  • P/E Ratio
  • BIIB $15.27
  • TXT $17.75
  • Revenue Growth
  • BIIB 4.77
  • TXT 1.83
  • 52 Week Low
  • BIIB $110.04
  • TXT $57.70
  • 52 Week High
  • BIIB $175.86
  • TXT $87.96
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 74.64
  • TXT 46.32
  • Support Level
  • BIIB $151.83
  • TXT $78.84
  • Resistance Level
  • BIIB $157.79
  • TXT $83.30
  • Average True Range (ATR)
  • BIIB 5.59
  • TXT 1.56
  • MACD
  • BIIB 1.37
  • TXT 0.18
  • Stochastic Oscillator
  • BIIB 95.37
  • TXT 45.51

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About TXT Textron Inc.

Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial contains the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.

Share on Social Networks: